A review takes up two problems that biologic therapy has not solved: patients who respond inadequately to agents targeting the IL-23 and IL-17 axis, and relapse after treatment is stopped. Its proposal is that immune-centred therapy leaves out the keratinocyte, which is not a passive target but an active amplifier of inflammation and a contributor to disease persistence.
From that starting point the authors set out an immune-epidermal dual-targeting framework built around feedback loops between immune cells and keratinocytes, with three possible routes to implementing it: combination therapy, single agents that hit both compartments, and blockade of bridging nodes within the feedback circuits. They also assess what multi-omics, organoid and engineered skin models, and precision local delivery might contribute, and are explicit about the limits of each.
The authors are careful to say this is not meant to replace current treatment paradigms, and a practising dermatologist should read it the same way. Nothing here alters biologic selection. What it offers is a better account to give a patient whose psoriasis relapses within weeks of stopping an otherwise effective drug - the epidermal side of the loop was never treated, so the disease did not need to be re-triggered to return.
- No change to biologic choice or sequencing; this is a mechanistic framework, not a guideline
- Useful language for explaining post-discontinuation relapse to a patient
- Keeps topical therapy in the picture for patients on systemic treatment rather than treating it as failure
- Most components are still at the stage of mechanistic research, as the authors state
- Watch for dual-targeting agents in trial, rather than expecting a change in practice now
Why it matters
It reframes post-discontinuation relapse as an untreated compartment rather than as an inevitable feature of the disease.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for dermatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free